Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine

Author： Bou J.   Domenech T.   Puig J.   Heredia A.   Gras J.   Fernandez-Forner D.   Beleta J.   Palacios J.M.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.410, Iss.1, 2000-12, pp. : 33-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT 1B/1D Receptor Agonist for the Treatment of Migraine

By McEnroe Janet D.   Fleishaker Joseph C.  

Clinical Pharmacokinetics, Vol. 44, Iss. 3, 2005-01 ,pp. : 237-246

Adis International

Access to resources Recommend Favorite

Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine

By Gras J.   Cardelus I.   Llenas J.   Palacios J.M.  

European Journal of Pharmacology, Vol. 410, Iss. 1, 2000-12 ,pp. : 53-59

Elsevier

Access to resources Recommend Favorite

Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine

By Dahlof C.   Lines C.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 671-685

Informa Healthcare

Access to resources Recommend Favorite

Cranial vascular effects of zolmitriptan, a centrally active 5-HT 1B/1D receptor partial agonist for the acute treatment of migraine

By MacLennan S.J.   Cambridge D.   Whiting M.V.   Marston C.   Martin G.R.  

European Journal of Pharmacology, Vol. 361, Iss. 2, 1998-11 ,pp. : 191-197

Elsevier

Access to resources Recommend Favorite

Is the 5-HT 7 receptor involved in the pathogenesis and prophylactic treatment of migraine?

By Terron J.A.  

European Journal of Pharmacology, Vol. 439, Iss. 1, 2002-03 ,pp. : 1-11

Elsevier

Access to resources Recommend Favorite